Burning Rock Biotech Ltd
NASDAQ:BNR
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
CN |
Burning Rock Biotech Ltd
NASDAQ:BNR
|
87.3m USD | 0.8 | ||
US |
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 27.2 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
144.5B USD | 23.2 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.4B USD | 5.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.6B USD | 3.7 | ||
AU |
CSL Ltd
ASX:CSL
|
132B AUD | 5 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.5B USD | 3.6 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 16.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 3 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
30.3B USD | 2 | ||
KR |
Celltrion Inc
KRX:068270
|
36.6T KRW | 2.2 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.